CERo Total Stockholder Equity from 2010 to 2024

CEROW Stock   0.01  0  14.29%   
CERo Therapeutics Total Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Total Stockholder Equity is likely to outpace its year average in 2024. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2010-12-31
Previous Quarter
-14.2 M
Current Value
-13.5 M
Quarterly Volatility
74.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check CERo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CERo Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 121.5 K, Interest Income of 121.5 K or Depreciation And Amortization of 2.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. CERo financial statements analysis is a perfect complement when working with CERo Therapeutics Valuation or Volatility modules.
  
Check out the analysis of CERo Therapeutics Correlation against competitors.

Latest CERo Therapeutics' Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of CERo Therapeutics Holdings over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. CERo Therapeutics' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CERo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Slightly volatile
   Total Stockholder Equity   
       Timeline  

CERo Total Stockholder Equity Regression Statistics

Arithmetic Mean134,982,802
Geometric Mean92,122,520
Coefficient Of Variation55.04
Mean Deviation57,355,734
Median170,830,135
Standard Deviation74,296,480
Sample Variance5520T
Range185M
R-Value(0.70)
Mean Square Error3056.7T
R-Squared0.49
Significance0
Slope(11,579,350)
Total Sum of Squares77279.5T

CERo Total Stockholder Equity History

2024-13.5 M
2023-14.2 M
20222.5 M

About CERo Therapeutics Financial Statements

CERo Therapeutics investors use historical fundamental indicators, such as CERo Therapeutics' Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CERo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Stockholder Equity-14.2 M-13.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for CERo Stock Analysis

When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.